Global trends in molecular epidemiology of HIV-1 during 2000-2007 by Hemelaar, Joris et al.
Global trends in molecular epidemiology of HIV-1 during 2000–
2007
Joris Hemelaar1,*, Eleanor Gouws2, Peter D. Ghys2, Saladin Osmanov3, and WHO-UNAIDS
Network for HIV Isolation and Characterisation
1Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe
Hospital, Oxford, United Kingdom 2Epidemiology and Analysis Division, UNAIDS, Geneva,
Switzerland 3WHO-UNAIDS HIV Vaccine Initiative, World Health Organisation, Geneva,
Switzerland
Abstract
Objective—To estimate the global and regional distribution of HIV-1 subtypes and recombinants
between 2000 and 2007.
Design—Country-specific HIV-1 molecular epidemiology data were combined with estimates of
the number of HIV-infected people in each country.
Method—Cross-sectional HIV-1 subtyping data were collected from 65913 samples in 109
countries between 2000 and 2007. The distribution of HIV-1 subtypes in individual countries was
weighted according to the number of HIV-infected people in each country to generate estimates of
regional and global HIV-1 subtype distribution for the periods 2000–2003 and 2004–2007.
Results—Analysis of the global distribution of HIV-1 subtypes and recombinants in the two time
periods indicated a broadly stable distribution of HIV-1 subtypes worldwide with a notable
increase in the proportion of circulating recombinant forms (CRFs), a decrease in unique
recombinant forms (URFs), and an overall increase in recombinants. In 2004–2007, subtype C
accounted for nearly half (48%) of all global infections, followed by subtypes A (12%) and B
(11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%) and D(2%). Subtypes F, H, J and K
together cause fewer than 1% of infections worldwide. Other CRFs and URFs are each responsible
for 4% of global infections, bringing the combined total of worldwide CRFs to 16% and all
recombinants (CRFs plus URFs) to 20%.
Conclusions—The global and regional distributions of individual subtypes and recombinants
are broadly stable, although CRFs may play an increasing role in the HIV pandemic. The global
diversity of HIV-1 poses a formidable challenge to HIV vaccine development.
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Introduction
HIV-1 remains a global health problem of unprecedented dimensions, with an estimated
33.4 million people living with HIV in 2008. The pandemic is dynamic, with 2.7 million
new infections and 2 million deaths occurring in 2008 [1].
HIV originated from multiple zoonotic transmissions of simian immunodeficiency virus
(SIV) from non-human primates to humans in West and Central Africa in the early 1900s.
HIV-1 group M, the pandemic branch of HIV, originates from SIVcpz in the chimpanzee
Pan troglodytes troglodytes [2]. After transmission to humans, while still confined to
western-central Africa, HIV-1 group M diversified into genetic subtypes (named A-D, F-H
and J-K) in the first half of the 20th century [3]. HIV genetic variability is the result of the
high mutation and recombination rates of the reverse transcriptase enzyme, together with
high rates of virus replication. Recombinants between subtypes are designated as circulating
recombinant forms (CRFs; 48 different CRFs have been described so far [4]) if fully
sequenced and found in three or more epidemiologically unlinked individuals, and unique
recombinant forms (URFs) if not meeting these criteria [5]. In the second half of the 20th
century the global spread of HIV-1 group M took place resulting in the differential global
distribution of HIV-1 subtypes and recombinants [6].
HIV diversity impacts HIV diagnosis and viral load measurements [7, 8] and may affect the
response to antiretroviral treatment and the emergence of drug resistance [9, 10]. Subtypes
may differ in the rate of disease progression [11–13] and some evidence suggests that
subtypes are transmitted at different rates [14, 15].
HIV infection in humans induces humoral and cellular immune responses which control
primary viraemia without completely eliminating infection due to the rapid selection of
immune-escape mutants [16, 17]. While the induction of neutralising antibodies and
effective CTL responses against HIV-1 through vaccination has proven extremely difficult,
an even greater challenge is posed by the extreme genetic diversity of the virus and its
continuing evolution [18].
Genetic variation within a subtype is in the order of 8–17%, whereas variation between
subtypes is usually between 17–35 %, depending on the subtypes and genome regions
examined [19]. This degree of diversity is likely to limit the intra- and inter-subtype cross-
reactivity of immune responses [20]. To increase the likelihood of vaccine-induced immune
responses cross-reacting with circulating strains, immunogens should match as closely as
possible viral sequences circulating in the target population [21]. Candidate HIV vaccines
tested in efficacy trials to date have been based on primary sequences of subtype B and
CRF01_AE [22–24]. Recent encouraging results of a phase III HIV-1 vaccine efficacy trial
in Thailand emphasise the importance of further studies on global and regional HIV
diversity to inform rational vaccine design and development [24].
Data on the global distribution of HIV subtypes is limited. HIV sequences deposited in the
Los Alamos sequence database are not representative for the distributions in the countries of
origin [4]. Some studies have relied on pooling published data from a wide range of years,
an approach which is hampered by publication bias and a lack of information on trends [25].
Here we present an analysis of the global and regional distribution of HIV-1 subtypes and
recombinants for the periods 2000–2003 and 2004–2007 using a combination of cross-
sectional country-specific HIV-1 molecular epidemiology data, derived from published and
unpublished sources, and estimates of the number of HIV-infected people in each country.
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Methods
Country-specific cross-sectional subtype distribution data
Data on the distribution of HIV-1 subtypes and recombinants in individual countries were
obtained from researchers in the field and from a comprehensive literature review. Research
laboratories across the globe specialising in subtyping of HIV-1 samples were solicited for
cross-sectional HIV-1 subtyping data of samples collected between 2000 and 2007. The
Medline literature database was searched for HIV-1 subtyping data for each country using
the terms “HIV”, “subtype” and the relevant country names. All potentially relevant articles
in English were retrieved and HIV-1 subtyping data from samples collected between 2000–
2007 were included in our study. Data submitted to us and derived from the literature were
combined to determine the overall proportions of HIV-1 subtypes and recombinants in each
country. In addition to information on HIV-1 subtypes, the data sets included country (and
region/city) of sample origin, sampling year, transmission route/risk group, detection
method, and the genome segment(s) analysed. Overall, subtyping data of 41.8% of the
samples originated from previously unpublished data by members of the WHO-UNAIDS
Network for HIV Isolation and Characterisation, 35.6% were derived from the published
literature, and 22.6% were both submitted to us and published.
Global HIV-1 epidemiology and regional country groupings
Country-specific HIV-1 epidemiology data were obtained from the UNAIDS/WHO
estimates of the burden of HIV-1 in the years 2000 through 2007 [26]. For each country the
average number of HIV-1 infections in the periods of 2000–2003 and 2004–2007 was
determined and used in further analysis.
Countries were grouped in geographical regions according to the UNAIDS classification
[26], with some modifications. Sub-Saharan Africa was divided into five separate regions
(West, East, Central and Southern Africa, and Ethiopia), because the region has the largest
number of HIV-1 infections and a high level of regional HIV-1 subtype diversity. India and
Ethiopia were analysed separately as most infections were caused by a single subtype (C),
which would have skewed the distribution in their respective regions, where other subtypes
predominate. These modifications resulted in the final grouping of all countries into 15
regions, as specified in the legend of Table 2.
Data analysis
The HIV-1 subtype distribution in each region was determined by first multiplying the
proportions of all subtypes and recombinants in each country in each period (2000–2003 or
2004–2007) by the estimated (average) number of people living with HIV in the same
country in the relevant period. The resulting numbers of each subtype in each country in
each region were added up and used to calculate the proportions of the different subtypes
and recombinants in each region. Countries for which no HIV-1 subtyping data had been
obtained were not included in this part of the analysis.
To determine the global distribution of HIV-1 variants, the regional proportions of HIV-1
subtypes and recombinants were multiplied by the number of HIV-1 infected individuals in
each region (including countries for which no subtyping data were obtained). The resulting
total numbers of people living with each subtype in each region were added up and the
global distribution of HIV-1 subtypes and recombinants was derived.
To determine the spread over the regions of individual subtypes, the estimated number of
infections caused by a subtype in each region was taken as a proportion of the global
number of infections caused by that same subtype.
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Results
Primary HIV-1 subtype distribution data
HIV-1 subtype characterisation data were collected from a total of 65913 samples from
HIV-infected individuals in 109 countries between 2000 and 2007. For our analysis the data
were divided into two time periods (2000–2003 and 2004–2007) and 15 geographical
regions (Methods, Table1, legend to Table2). In 2000–2003, 39148 samples from 95
countries were analysed, and in 2004–2007, 26765 samples from 70 countries were
available.
Worldwide the countries for which HIV-1 subtype distribution data were collected
accounted for 94% and 90% of individuals living with HIV-1 in 2000–2003 and 2004–2007,
respectively (Table1, last column). In nine out of the 15 regions, for both time periods, the
countries with subtype data represented more than 90% of people living with HIV in the
region.
The number of samples analysed as a proportion of the number of people living with HIV
was higher in 2000–2003 than 2004–2007 globally as well as in all but two regions (Table1,
3rd last column). The proportion of the infected population sampled varied between regions
and was higher in the Americas, Western and Central Europe, East Asia, and Oceania,
whereas India, Middle East & North Africa, and sub-Saharan Africa were less well
represented.
Global distribution of HIV-1 subtypes and recombinants
The distribution of HIV-1 subtypes in individual countries was weighted according to the
number of HIV-infected people in each country to generate estimates of regional and global
HIV-1 subtype distribution for the 2000–2003 and 2004–2007 (Figure1,Table2A). In 2004–
2007 subtype C accounted for nearly half (48%) of all global infections. Subtypes A and B
caused 12% and 11% of infections, respectively, followed by CRF02_AG (8%), CRF01_AE
(5%), subtype G (5%) and D (2%). Subtypes F, H, J and K together caused fewer than 1% of
infections worldwide. Other CRFs and URFs are each responsible for 4% of global
infections, bringing the combined total of worldwide CRFs (CRF01_AE, CRF02_AG,
CRF03_AB and other CRFs) to 16% and all recombinants (all CRFs and URFs) to over 20%
(Figure1,Table2A).
Overall, the global distributions of subtypes were similar between 2000–2003 and 2004–
2007 and in line with previous estimates [4, 6, 25]. Three epidemiological trends were noted
(Table2A). Firstly, an increase in the global proportion (and absolute growth) of the
epidemics of subtypes A, F, G, H, CRF01_AE, CRF02_AG and other CRFs was observed.
Secondly, the epidemics caused by subtypes D, J, K, CRF03_AB and URFs decreased in
size and thus their proportion of the global total became smaller. Thirdly, the epidemics
caused by subtypes B and C grew at a rate below the average, resulting in a decrease of their
proportion of the global epidemic, though subtype C still caused the largest absolute
increase in number of infections.
The global proportion of all CRFs combined increased by 4.5%, which corresponds to a
50% increase in the number of infections. In contrast, the proportion of infections caused by
URFs diminished by 3.1%, a 39% decrease of the burden of URFs. Together, all
recombinants (CRFs & URFs) increased by 17%, resulting in a 1.4% increase in the
proportion of recombinant infections to a total of 20.5% (Table2A). These changes reflect a
widespread trend, as an increase in the proportion of other CRFs and a decrease in URFs is
widely observed in 10 of the 15 regions (Table2B). It is further notable that, among the
major subtypes, subtype A increased and subtype D decreased globally (Table2A).
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Regional distribution of HIV-1 subtypes and recombinants
The distribution of HIV-1 subtypes and recombinants in each region is strikingly different
across the world (Figure2, Table2B, and Supplemental Digital Content 1, which shows the
subtype distribution in individual countries in 2000–2003 and 2004–2007). Changes in
regional subtype distributions are shown in table 2B. The regional subtype distributions in
2004–2007 are discussed here.
The greatest diversity is found in Central Africa where all subtypes and many CRFs and
URFs are represented (Figure2, Table2B, and SDC1). The six countries in this region all
harbour a great subtype diversity, but differ in the dominant subtypes (see SDC1). In the
Democratic Republic of the Congo all subtypes, CRF01_AE, CRF02_AG and many other
CRFs and URFs are found, except subtype B (see SDC1).
In West Africa all subtypes are detected with the dominant variants being CRF02_AG and
subtype G. In East Africa the majority of infections are due to subtype A, with the remainder
due to subtypes C and D, and URFs. In Southern Africa, Ethiopia and India the epidemics
are nearly exclusively caused by subtype C.
Subtype B dominates in North America, the Caribbean, Latin America, Western and Central
Europe and Australia. In Western and Central Europe all major subtypes and many CRFs
and URFs are detected. The epidemic in Eastern Europe and Central Asia is dominated by
subtype A and subtype B.
In South and South-East Asia CRF01_AE is responsible for the vast majority of infections.
In this region the combined proportion of all recombinant infections is 86%, which is the
highest in the world. In East Asia the epidemic is dominated by CRF07_BC & CRF08_BC,
CRF01_AE, and subtype B. The Middle East and North Africa is mainly affected by
subtype B and various CRFs.
Global spread of individual HIV-1 subtypes and recombinants
The distribution of individual HIV-1 subtypes and recombinants across the globe is shown
in Figure3 and Supplemental Digital Content 2 and 3. The majority of global dominant
subtype C is present in Southern Africa and India, with further infections in East Africa and
Ethiopia (Table2). Subtype A is mainly found in East Africa and Eastern Europe & Central
Asia, with the remainder in West and Central Africa and South & South-East Asia. The
subtype B epidemic is more widely and evenly spread than the other subtypes. For eight
subtypes/CRFs analysed 95% of infections are contained in only three or fewer regions. In
contrast, 95% of subtype B is spread over 7 regions (Figure3, SDC2&3). Interestingly,
hardly any subtype B infections are found in sub-Saharan Africa.
CRF02_AG is the fourth largest variant globally and is concentrated in West Africa, with
smaller numbers in Central Africa and the Middle East & North Africa. CRF01_AE is the
fifth largest subtype and is found in South & South-East Asia, East Asia and a small number
in Central Africa.
Subtype G is concentrated in West and Central Africa. Subtype D is present mainly in
Eastern Africa, with further infections in Central and West Africa. Subtype F is widely and
evenly spread worldwide, whereas subtype H, J and K are found in Central, Southern and
West Africa. CRF03_AB does not play a significant role globally or regionally.
Other CRFs are differentially distributed over West Africa (mainly CRF06_cpx), East Asia
(mainly CRF07_BC & CRF08_BC in China), Central Africa (CRF11_cpx among others),
Latin America (CRF12_BF, CRF28_BF, CRF31_BC, CRF38_BF, and others), Middle East
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& North Africa (mainly CRF06_cpx), and South & South-East Asia (mainly CRF35_AD
and CRF07_BC). A wide variety of URFs is distributed over sub-Saharan Africa, Latin
America (mainly unique BF recombinants) and South and South-East Africa.
Discussion
The global distribution of HIV-1 subtypes was broadly stable over the 2000–2007 period,
with an overall increase in recombinants (Figure1,Table2A) and dynamic changes in some
regions (Figure2, Table2B, SDC1). The global HIV subtype distribution was broadly similar
to estimated distributions obtained using published data only, as well as estimates calculated
by combining country HIV subtype distributions in the Los Alamos database with the
country-specific numbers of HIV-infected people used in our study [4, 6, 25](data not
shown). The observed trends in subtype distribution between the periods were caused by an
interplay between changes in subtype distribution in countries and in the numbers of HIV-
infected people (Tables1&2, SDC1). These changes over an 8-year period are consistent
with a stabilising global epidemic with a significant annual turnover due to new infections
and deaths, and rapid growth of certain regional epidemics (Table1)[1].
Our study has some limitations. Some regions had poor coverage because of lack of data
(Caribbean, Oceania, Middle East and North Africa; Table 1, last column), some countries
and regions had small sample sizes, in particular those which harbour the largest number of
infections and have the highest subtype diversity (Table1), and only a small amount of data
were obtained from representative national surveys. Moreover, the heterogeneous nature of
the data sets from the two time periods precluded a direct comparison and statistical
analysis. Sampling biases may have occurred due to patient selection (risk groups, treatment
failure, disease progression), limited geographical coverage and consistency within
countries, and unknown dates and places of infection. In addition, subtyping methods used
and the type and number of genome segments analysed may have affected results. Finally,
publication bias may have occurred in the data derived from the literature.
We found a notable increase in the proportion of CRFs, a decrease in URFs and an overall
increase in recombinants, although no formal statistical test for trend was used (Table2A).
Detailed examination showed that these trends could not be attributed to the subtyping
methods used or the type and number of genome segments analysed in the different periods
(data not shown). However, given the relatively recent establishment of rules governing
CRF nomenclature [5], samples with discordant subtypes in different genome segments may
have been classified as recombinants (or URFs), before the relevant CRFs were
characterised, especially in the earlier time period. It is probable that the overall proportion
of recombinants is underestimated in both periods due to the limited number of full-length
sequences available (0.6–5%; data not shown).
Independent studies in Uganda, Tanzania and Kenya suggest that subtype D infection is
associated with faster disease progression than subtype A in populations where they co-
circulate, despite similar plasma viral loads [11–13]. In addition, a higher rate of
heterosexual transmission of subtype A than subtype D was reported [14]. A long term study
examining the subtype distribution in Kenya during the expanding epidemic found a
significant decrease in the proportion of subtype D and a slight increase in subtype A [27].
These reports are consistent with our findings of an increase in the proportion of subtype A
and a decrease in subtype D in East Africa and globally.
The explanations for the current global subtype distribution and the recent changes observed
are probably multifactorial and include founder effects, population growth and urbanisation,
and improved transport links and migration [3, 28]. It is uncertain at present whether
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biological properties of different subtypes and recombinants play a role in their differential
spread.
HIV diversity, in populations and in individuals, is one of the major challenges in HIV
vaccine development. It seems clear that vaccine immunogen sequence should match as
closely as possible the viral sequences circulating in the target population. Up to date and
accurate information on HIV subtype distribution is therefore essential, not least to ensure
that efforts and funding are allocated according to the regional and global impact of the
various HIV subtypes and recombinants. Our study highlights that the distribution of
subtypes and recombinants globally and regionally is extremely complex. This diversity
may be addressed by the use of consensus, ancestral, centre-of-tree or mosaic sequences in
vaccines [21, 29].
The challenges posed by the genetic diversity of the HIV-1 pandemic to prevention and
treatment efforts demand that global molecular epidemiology surveillance is continued and
improved. In particular, full length sequencing of samples obtained from nationally
representative surveys, taking account of geographical differences and differences in
transmission routes/risk groups, are urgently needed.
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Appendix
Contributing members of the WHO/UNAIDS Network for HIV Isolation and
Characterisation [name of contributor (country where contributor is based)]: S. Agwale
(Nigeria), J-P. Allain & L. Fischetti (UK), C. Archibald, J Brooks & M. Ofner (Canada), E.
Belabbes (Algeria), J. Brandful (Ghana), M. Bruckova & M. Linka (Czech Republic), F.
Buonaguro & L. Buonaguro (Italy), J. Carr (USA), D. Cooper, T. Kelleher, A. Carrera & P.
Cunningham (Australia), D. Dwyer & F. Raikanikoda (Australia), B. Ensoli & S. Butto
(Italy), M. Essex & V. Novitsky (USA), H. Fleury (France), F. Gao (USA), G-M. Gershy-
Damet (Zimbabwe), Z. Grossman & S. Maayan (Israel), X. He (China), D. Ho & L. Zhang
(USA), M. Hoelscher (Germany), M. Hosseinipour & J. van Oosterhout (Malawi), P.
Kaleebu & R. Goodall (Uganda), M. Kalish (USA), P. Kanki (USA), E. Karamov (Russian
Federation), D. Kombate-Noudjo & A. Dagnra (Togo), T. Leitner (USA), I. Lorenzana de
Rivera (Honduras), F. McCutchan (USA), F. Mhalu, W. Urassa, F. Mosha & D. Mloka
(Tanzania), M. Morgado (Brazil), J. Mullins, M. Campbell, C. Rousseau, J. Herbeck & M.
Rolland (USA), J. Najera & M. Thomson (Spain), P. Nyambi (USA), A. Papa (Greece), J.
Pape & C. Nolte (Haiti), M. Peeters (France), J-M. Reynes (Cambodia), M. Salminen
(Finland), H. Salomon & M. Carillo (Argentina), B. Schroeder (New Zealand), M. Segondy
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& B. Montes (France), J. Servais, A. Pelletier, K. Kayitenkore & J-C Karasi (Rwanda), R.
Shankarappa (USA), Y. Shao, X. He & J. Xu (China), T. Smolskaya (Russian Federation),
M. Soares & A. Tanuri (Brazil), E. Songok (Kenya), R. Sutthent (Thailand), Y. Takebe
(Japan), H. Ushijima & T. Quang (Japan & Vietnam), P. Van de Perre & Méda (Burkina
Faso), A. van Sighem (Netherlands), A-M. Vandamme & J. Vercauteren (Belgium), C.
Williamson, H. Bredell & D. Stewart (South Africa), D. Wolday (Ethiopia), J. Xu (China),
C. Yang (USA), D. Yirrell (UK), L. Zhang, R. Zhang & Z. Chen (China).
Composition of regions
Countries are underlined if HIV-1 subtype distribution data was obtained for the period
2000–2003 (hatched;   ), 2004–2007 (single underlined;   ), or both 2000–2003 & 2004–
2007 (double underlined;    ).
North America: Canada, USA;
Caribbean: Bahamas, Barbados, Cuba, Dominican Republic, Haiti, Jamaica, Trinidad and
Tobago;
Latin America: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El
Salvador, Guatemala, Guyana, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru,
Suriname, Uruguay, Venezuela;
Western and Central Europe: Albania, Austria, Belgium, Czech Republic, Denmark,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Luxembourg,
Malta, Montenegro, Netherlands, Norway, Poland, Portugal, Serbia, Slovakia, Slovenia,
Spain, Sweden, Switzerland, The Former Yugoslav Republic Macedonia, the United
Kingdom;
Eastern Europe and Central Asia: Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina,
Bulgaria, Croatia, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of
Moldova, Romania, Russian Federation, Tajikistan, Turkmenistan, Ukraine, Uzbekistan;
India
South and South-East Asia (excl. India): Afghanistan, Bangladesh, Bhutan, Brunei
Darussalam, Cambodia, Indonesia, Iran (Islamic Republic of), Lao People’s Democratic
Republic, Malaysia, Maldives, Myanmar, Nepal, Pakistan, Philippines, Singapore, Sri
Lanka, Thailand, Timor-Leste, Viet Nam;
East Asia: China, Democratic People’s Republic of Korea, Japan, Mongolia, Republic of
Korea;
Oceania: Australia, Fiji, New Zealand, Papua New Guinea;
Middle East and North Africa: Algeria, Bahrain, Cyprus, Egypt, Iraq, Jordan, Kuwait,
Lebanon, Libyan Arab Jamahiriya, Morocco, Oman, Qatar, Saudi Arabia, Sudan, Syrian
Arab Republic, Tunisia, Turkey, United Arab Emirates, Yemen;
West Africa: Benin, Burkina Faso, Cameroon, Côte d'Ivoire, Equatorial Guinea, Gambia,
Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra
Leone, Togo;
East Africa (excl. Ethiopia): Burundi, Djibouti, Eritrea, Kenya, Mauritius, Rwanda, Somalia,
Uganda, United Republic of Tanzania; Ethiopia;
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Central Africa: Angola, Central African Republic, Chad, Congo, Democratic Republic of the
Congo, Gabon;
Southern Africa: Botswana, Comoros, Lesotho, Madagascar, Malawi, Mozambique,
Namibia, South Africa, Swaziland, Zambia, Zimbabwe.
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Figure 1. Global distribution of HIV-1 subtypes and recombinants in 2000–2003 and 2004–2007
The number of infections caused by HIV-1 subtypes and recombinants are represented as a
proportion of the global total number of people living with HIV-1 in 2000–2003 (A.) and
2004–2007 (B.) (see Table 2A). The colours representing the different HIV-1 subtypes are
indicated in the legend on the left-hand side of the figure.
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Figure 2. Regional distribution of HIV-1 subtypes and recombinants in 2000–2003 and 2004–
2007
The world was divided into 15 regions consisting of groups of countries as specified in the
Methods. Countries forming a region are shaded in the same colour. Pie-charts representing
the distribution of HIV-1 subtypes and recombinants in each region in 2000–2003 (A.) and
2004–2007 (B.) are superimposed on the regions. The pie-charts were prepared using the
data presented in Table 2B. The colours representing the different HIV-1 subtypes are
indicated in the legend on the left-hand side of the figure. The relative surface areas of the
pie-charts correspond to the relative numbers of people living with HIV in the regions
(Table 1).
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Disclaimer: The boundaries and names shown and the designations used on this map do not
imply the expression of any opinion whatsoever on the part of the World Health
Organisation or the Joint United Nations Programme on HIV/AIDS (UNAIDS) concerning
the legal status of any country, territory, city or area or of its authorities, or concerning the
delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate
borderlines for which there may not yet be full agreement.
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Figure 3. Global distribution of individual HIV-1 subtypes and recombinants in 2004–2007
For each subtype/recombinant indicated each of the 15 regions is shaded according to the
proportion of the global number of infections caused by the subtype/recombinant present in
each region.
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